Latest News

OLPs did not affect migraine frequency but did subjectively improve QoL, with authors noting they may have a role as a supportive treatment option for select patients.

Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.

As dementia care grows more complex and more promising, the role for front-line clinicians is becoming more nuanced and more essential.

AstraZeneca will share the positive topline 24-hour BP monitoring data with global regulatory authorities and present findings at the 2025 AHA Scientific Sessions.

Discover essential insights and innovative strategies at FMX 2025, featuring key topics like AI in healthcare and advancements in family medicine.

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

Sarah C. Nosal, MD, FAAFP, takes the helm as AAFP President, emphasizing community-focused family medicine and innovative healthcare solutions.

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.